Doesnt seem to mention anywhere that the others are approved by CMS or KP for that matter unless I have missed something.
The others may well have the long approval road ahead of them.
Seems like the references are a bit dated as well.
Printable View
Doesnt seem to mention anywhere that the others are approved by CMS or KP for that matter unless I have missed something.
The others may well have the long approval road ahead of them.
Seems like the references are a bit dated as well.
Whether or not the competition are approved seems like an essential piece of research to anyone looking to invest in peb.
The competition is only competition if they have significant data to back up their claim. PEB have spent 7 years with vast amounts of proof whereas the others are only vertically just pilot schemes as far as I can see. Maybe competition in 5 or 6 years.
PEB are also now looking at prostate bio markers, along with other cancers, so future is bright.
Bladder cancer is what they have concentrated on first an obvious one because their research showed that this was the most problematic to urologists given the uncertainty of cystoscopys and the procedural invasive nature of them
Bang, Bang, Bang, Bang with a mechanical sound!
Come on guys....why are you terrorizing the rest of us? :ohmy:
A recent post provided a link to DDs address to a conference where he sketched the history of PEB and its sucess in building a database with biomarkers for colorectal, prostate, gastric and bladder cancers and their decision to try to bring CX Bladder to market first.